April 2023

Guselkumab, um inibidor seletivo da subunidade p19 da interleucina-23, resolve a dactilite em pacientes com artrite psoriásica ativa: Resultados agrupados até a semana 52 de dois estudos de fase 3

ACR Open Rheumatol. 2023;5(4):227–240 doi 10.1002/acr2.11537

Post hoc analysis of guselkumab, Phase 3 DISCOVER-1 and -2 studies finds that 75% of guselkumab-randomised patients have complete resolution of dactylitis through one year.

Keywords:

Eficácia e segurança multidomínio de guselkumabe durante um ano em pacientes com artrite psoriática ativa com e sem exposição prévia a inibidores do fator de necrose tumoral: análise do estudo de fase 3, randomizado, controlado com placebo DISCOVER-1

ACR Open Rheumatol. 2023 doi: 10.1002/acr2.11523

TNF inhibitors (TNFi) are one main mode of therapy in patients with PsA who fail to respond to csDMARDs. However, they have a primary treatment failure rate of 40% and only a modest target of ≥20% ACR20 response. The objective of this study was to evaluate efficacy and safety of guselkumab, interleukin-23 inhibitor in the DISCOVER-1 study with active PsA patients by prior use of TNFi.

Keywords:

March 2023

Baixas Taxas de Progressão Radiográfica Associadas com Eficácia Clínica em até 2 anos de Seguimento Após Tratamento com Guselkumab: Resultados de um Ensaio Clínico Randomizado de Fase 3, Duplo-Cego, Controlado com Placebo com Pacientes Naïve a Biológicos com Artrite Psoriásica Ativa

RMD Open. 2023 doi: 10.1136/rmdopen-2022-002789

Data from this paper provides a robust analysis of radiographic progression through 2 years in a phase 3 study of guselkumab in patients with PsA. This study sought to evaluate the relationship between radiographic progression and clinical outcomes in post hoc analyses of patients with PsA receiving up to 2 years of guselkumab therapy in DISCOVER-2.

Keywords: